Marc C Chamberlain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3167840/publications.pdf

Version: 2024-02-01

151 papers

12,140 citations

²⁶⁶³⁰
56
h-index

28297 105 g-index

187 all docs

187 docs citations

times ranked

187

11209 citing authors

#	Article	IF	CITATIONS
1	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
2	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology, 2010, 28, 1168-1174.	1.6	450
3	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. Journal of Clinical Oncology, 1999, 17, 3110-3116.	1.6	393
4	Leptomeningeal metastasis. Neurology, 1990, 40, 435-435.	1.1	244
5	Adult Primary Intradural Spinal Cord Tumors: A Review. Current Neurology and Neuroscience Reports, 2011, 11, 320-328.	4.2	240
6	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology, 2014, 16, 829-840.	1.2	198
7	Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment. Seminars in Oncology, 2009, 36, S35-S45.	2.2	189
8	Radiographic patterns of relapse in glioblastoma. Journal of Neuro-Oncology, 2011, 101, 319-323.	2.9	183
9	Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology, 2017, 19, i1-i24.	1.2	171
10	Temozolomide for treatment-resistant recurrent meningioma. Neurology, 2004, 62, 1210-1212.	1.1	167
11	Neoplastic Meningitis. Oncologist, 2008, 13, 967-977.	3.7	167
12	Leptomeningeal metastasis. Current Opinion in Oncology, 2010, 22, 627-635.	2.4	159
13	Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology, 2017, 19, now183.	1.2	157
14	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Review of Neurotherapeutics, 2010, 10, 1537-1544.	2.8	155
15	Prognostic significance of sup 111 Indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology, 1996, 46, 1674-1677.	1.1	151
16	Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. Journal of Neurosurgery, 1997, 87, 694-699.	1.6	148
17	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-Oncology, 2014, 16, 1176-1185.	1.2	141
18	PET imaging in patients with brain metastasisâ€"report of the RANO/PET group. Neuro-Oncology, 2019, 21, 585-595.	1.2	139

#	Article	IF	CITATIONS
19	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	137
20	Carcinoma Meningitis Secondary to Non–Small Cell Lung Cancer. Archives of Neurology, 1998, 55, 506.	4.5	130
21	Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. Journal of Neuro-Oncology, 2013, 114, 237-240.	2.9	124
22	Radioisotope CSF flow studies in leptomeningeal metastases. , 1998, 38, 135-140.		117
23	Salvage therapy with single agent bevacizumab for recurrent glioblastoma. Journal of Neuro-Oncology, 2010, 96, 259-269.	2.9	117
24	Leptomeningeal metastases: a review of evaluation and treatment., 1998, 37, 271-284.		113
25	Bevacizumab for the Treatment of Recurrent Glioblastoma. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S7232.	1.3	113
26	A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology, 2008, 10, 208-215.	1.2	109
27	Comparative spine imaging in leptomeningeal metastases. Journal of Neuro-Oncology, 1995, 23, 233-238.	2.9	108
28	Interferonâ€Î± for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer, 2008, 113, 2146-2151.	4.1	104
29	Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer, 2010, 116, 1947-1952.	4.1	99
30	Salvage chemotherapy With CPT-11 for recurrent meningioma. Journal of Neuro-Oncology, 2006, 78, 271-276.	2.9	97
31	Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy., 1997, 35, 55-64.		95
32	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 2017, 19, 12-21.	1.2	94
33	A Phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer, 2002, 94, 2675-2680.	4.1	91
34	Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1191-1202.	4.9	89
35	Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. Journal of Neuro-Oncology, 2005, 75, 71-83.	2.9	83
36	High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro-Oncology, 2010, 12, 736-744.	1.2	83

#	Article	IF	Citations
37	Salvage chemotherapy for recurrent spinal cord ependymona. Cancer, 2002, 95, 997-1002.	4.1	82
38	Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. Journal of Neuro-Oncology, 2012, 107, 315-321.	2.9	81
39	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology, 2018, 20, 249-258.	1.2	78
40	Chemotherapy-Related Neurotoxicity. Current Neurology and Neuroscience Reports, 2016, 16, 81.	4.2	77
41	Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer, 2006, 106, 2021-2027.	4.1	74
42	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncology, 2018, 20, 13-23.	1.2	74
43	Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 2002, 56, 183-188.	2.9	73
44	Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. Journal of Neuro-Oncology, 2012, 109, 143-148.	2.9	73
45	Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer, 2003, 97, 3053-3060.	4.1	70
46	Bevacizumab for recurrent alkylatorâ€refractory anaplastic oligodendroglioma. Cancer, 2009, 115, 1734-1743.	4.1	70
47	A comparison between ventricular and lumbar cerebrospinal `uid cytology in adult patients with leptomeningeal metastases. Neuro-Oncology, 2001, 3, 42-45.	1.2	69
48	Central Nervous System Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1517-1523.	4.9	69
49	SEQUENTIAL SALVAGE CHEMOTHERAPY FOR RECURRENT INTRACRANIAL HEMANGIOPERICYTOMA. Neurosurgery, 2008, 63, 720-727.	1.1	66
50	Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. Journal of Neuro-Oncology, 2011, 104, 765-771.	2.9	66
51	Central Nervous System Cancers Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 644.	4.9	66
52	Cerebrospinal fluid-disseminated meningioma. Cancer, 2005, 103, 1427-1430.	4.1	62
53	Temozolomide for recurrent lowâ€grade spinal cord gliomas in adults. Cancer, 2008, 113, 1019-1024.	4.1	62
54	Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer, 2010, 116, 3988-3999.	4.1	62

#	Article	IF	Citations
55	Combined-modality Treatment of Leptomeningeal Gliomatosis. Neurosurgery, 2003, 52, 324-330.	1.1	61
56	Intracranial meningiomas: diagnosis and treatment. Expert Review of Neurotherapeutics, 2004, 4, 641-648.	2.8	59
57	Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. Journal of Neuro-Oncology, 2009, 91, 359-367.	2.9	59
58	Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1268-1278.	1.1	58
59	Neuraxis imaging in leptomeningeal metastasis: A retrospective case series Journal of Clinical Oncology, 2012, 30, 2046-2046.	1.6	58
60	Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatric Neurology, 2001, 24, 117-121.	2.1	57
61	Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer, 2004, 100, 1213-1220.	4.1	56
62	Leptomeningeal metastasis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 169-204.	1.8	55
63	Chronic oral VP-16 for recurrent medulloblastoma. Pediatric Neurology, 1997, 17, 230-234.	2.1	54
64	Neoplastic Meningitis–Related Prognostic Significance of the Karnofsky Performance Status. Archives of Neurology, 2009, 66, 74-8.	4.5	53
65	Anaplastic astrocytoma. CNS Oncology, 2016, 5, 145-157.	3.0	51
66	Treatment of intracranial metastatic esthesioneuroblastoma. Cancer, 2002, 95, 243-248.	4.1	47
67	Leptomeningeal metastasis. Current Opinion in Neurology, 2009, 22, 665-674.	3.6	47
68	A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC). Journal of Neuro-Oncology, 2014, 118, 335-343.	2.9	46
69	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Journal of Neuro-Oncology, 2017, 133, 561-569.	2.9	43
70	Temozolomide for recurrent intracranial supratentorial platinumâ€refractory ependymoma. Cancer, 2009, 115, 4775-4782.	4.1	42
71	Medical treatment of recurrent meningiomas. Expert Review of Neurotherapeutics, 2011, 11, 1425-1432.	2.8	41
72	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology, 2018, 20, 259-267.	1.2	41

#	Article	IF	CITATIONS
73	Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors. Cancer Control, 2017, 24, 1-16.	1.8	40
74	Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. Journal of Neuro-Oncology, 2011, 102, 427-432.	2.9	39
75	Neoplastic meningitis-related encephalopathy. Neurology, 2004, 63, 2159-2161.	1.1	37
76	Treatment options for glioblastoma. Neurosurgical Focus, 2006, 20, E19.	2.3	37
77	A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. Journal of Neuro-Oncology, 2007, 82, 207-209.	2.9	37
78	Prognostic significance of relative $1p/19q$ codeletion in oligodendroglial tumors. Journal of Neuro-Oncology, 2015, 125, 249-251.	2.9	37
79	The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Current Opinion in Oncology, 2012, 24, 666-671.	2.4	35
80	Neoplastic meningitis. Current Neurology and Neuroscience Reports, 2008, 8, 249-258.	4.2	34
81	Neoplastic meningitis. Cancer, 2009, 115, 1941-1946.	4.1	34
82	Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. Journal of Neuro-Oncology, 2009, 91, 271-277.	2.9	34
83	A novel treatment for glioblastoma: integrin inhibition. Expert Review of Neurotherapeutics, 2012, 12, 421-435.	2.8	34
84	Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. Journal of Neuro-Oncology, 2014, 118, 155-162.	2.9	34
85	Brain metastases: a medical neuro-oncology perspective. Expert Review of Neurotherapeutics, 2010, 10, 563-573.	2.8	33
86	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with highâ \in grade gliomas. Cancer, 2016, 122, 582-587.	4.1	33
87	Myelomatous meningitis. Cancer, 2008, 112, 1562-1567.	4.1	32
88	Intracerebral meningiomas. Current Treatment Options in Neurology, 2004, 6, 297-305.	1.8	31
89	Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncology, 2013, 2, 121-128.	3.0	31
90	Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. Journal of Neuro-Oncology, 2015, 124, 317-323.	2.9	31

#	Article	IF	Citations
91	Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma. Journal of Neuro-Oncology, 2009, 95, 285-288.	2.9	30
92	IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncology, 2013, 2, 227-235.	3.0	30
93	Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemotherapy and Pharmacology, 1989, 23, 301-307.	2.3	29
94	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
95	Neurotoxicity of Cancer Treatment. Current Oncology Reports, 2010, 12, 60-67.	4.0	27
96	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-Oncology, 2020, 22, 1505-1515.	1.2	27
97	Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. Journal of Neuro-Oncology, 2009, 93, 229-232.	2.9	26
98	Salvage therapy with single agent bendamustine for recurrent glioblastoma. Journal of Neuro-Oncology, 2011, 105, 523-530.	2.9	25
99	Radiation-Induced Myelopathy. Archives of Neurology, 2011, 68, 1608.	4.5	25
100	Intradural intramedullary spinal cord metastasis due to mesothelioma. Journal of Neuro-Oncology, 2010, 97, 133-136.	2.9	24
101	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-Oncology, 2018, 20, 1411-1418.	1.2	24
102	Salvage chemotherapy with CPTâ€11 for recurrent temozolomideâ€refractory anaplastic astrocytoma. Cancer, 2008, 112, 2038-2045.	4.1	23
103	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. Current Neurology and Neuroscience Reports, 2016, 16, 15.	4.2	23
104	High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. Journal of Neuro-Oncology, 2016, 126, 545-550.	2.9	22
105	Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics, 2010, 10, 547-561.	2.8	20
106	Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases. Cancer Control, 2017, 24, 22-32.	1.8	20
107	CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. Journal of Neuro-Oncology, 2008, 89, 231-238.	2.9	19
108	Neoplastic Meningitis and Metastatic Epidural Spinal Cord Compression. Hematology/Oncology Clinics of North America, 2012, 26, 917-931.	2.2	19

#	Article	IF	CITATIONS
109	Neoplastic Meningitis. Seminars in Neurology, 2004, 24, 363-374.	1.4	18
110	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. CNS Oncology, 2015, 4, 381-386.	3.0	18
111	Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. Journal of Neuro-Oncology, 2015, 122, 329-338.	2.9	18
112	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 2007, 110, 1698-1698.	1.4	17
113	CSF CA 15-3 in breast cancer-related leptomeningeal metastases. Journal of Neuro-Oncology, 2014, 117, 117-124.	2.9	17
114	Recurrent ganglioglioma in adults treated with BRAF inhibitors. CNS Oncology, 2016, 5, 27-29.	3.0	17
115	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide,) Tj ETQq1 1 0. and Leukemia, 2017, 17, 225-230.	.784314 r 0.4	gBT /Overlo
116	O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma. BBA Clinical, 2015, 3, 1-10.	4.1	16
117	Prolonged survival of patients with breast cancer-related leptomeningeal metastases. Anticancer Research, 2013, 33, 2057-63.	1.1	16
118	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
119	Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?. CNS Oncology, $2013, 2, 1-5$.	3.0	11
120	Flow-Related Aneurysm within Glioblastoma: A Case Report and Review of Literature. World Neurosurgery, 2016, 89, 729.e1-729.e6.	1.3	11
121	Leukemia and the nervous system. Current Oncology Reports, 2005, 7, 66-73.	4.0	10
122	Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Expert Review of Neurotherapeutics, 2012, 12, 929-936.	2.8	10
123	Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Reports in Oncology, 2015, 8, 72-77.	0.7	10
124	Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases. Anti-Cancer Drugs, 2013, 24, 1093-1097.	1.4	9
125	Risk of neoplastic meningitis following surgical resection of cerebellar metastases. Journal of Neuro-Oncology, 2008, 89, 105-107.	2.9	8
126	Anaplastic astrocytomas: biology and treatment. Expert Review of Neurotherapeutics, 2008, 8, 575-586.	2.8	8

#	Article	IF	CITATIONS
127	Teaching Neuro <i>Images</i> : Sacral spine chloroma. Neurology, 2013, 81, e87.	1.1	8
128	Central Nervous System Involvement in Cutaneous T-Cell Lymphoma: 2 Illustrative Cases and a Review of Current Literature. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e25-e30.	0.4	6
129	Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series. Journal of Neuro-Oncology, 2013, 113, 27-32.	2.9	5
130	Are Prognostic Factors for Leptomeningeal Metastases Defined Sufficiently to Permit Tailored Treatment?. Journal of Thoracic Oncology, 2013, 8, e66-e67.	1.1	4
131	Is the volume of low-grade glioma measurable and is it clinically relevant?. Neuro-Oncology, 2014, 16, 1027-1028.	1.2	4
132	Bevacizumab and other novel therapies for recurrent oligodendroglial tumors. CNS Oncology, 2015, 4, 333-339.	3.0	4
133	Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. Journal of Neuro-Oncology, 2017, 131, 507-516.	2.9	4
134	Is there a role for vaccine-based therapy in recurrent glioblastoma?. Neuro-Oncology, 2014, 16, 757-757.	1.2	3
135	Neoplastic meningitis-related encephalopathy. Journal of Neuro-Oncology, 2005, 72, 185-189.	2.9	2
136	Glioblastoma in the Elderly. Cancer Treatment and Research, 2015, 163, 159-170.	0.5	2
137	Lymphomatous meningitis as a presentation of non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2011, 9, 419-20.	0.3	2
138	Lymphomatous Meningitis. American Journal of Cancer, 2002, 1, 423-434.	0.4	1
139	10 Questions About the Use of Bevacizumab in the Management of Recurrent Malignant Gliomas. Neurologist, 2010, 16, 56-60.	0.7	1
140	Neuro-oncology: a selected review of ASCO 2011 abstracts. Expert Review of Neurotherapeutics, 2011, 13, 1371-1377.	2.8	1
141	Carcinomatous meningitis. Memo - Magazine of European Medical Oncology, 2012, 5, 205-209.	0.5	1
142	Lumbar spine neuroarthropathy (Charcot joint) caused by a myxopapillary ependymoma. Journal of Neuro-Oncology, 2014, 117, 375-376.	2.9	1
143	Chemotherapy for Brain Metastases due to Lung Cancer and Melanoma. Cancer Treatment and Research, 2007, 136, 199-213.	0.5	1
144	Response to Weltman and Fleury Malheiros, re Lassman et al Neuro-Oncology, 2012, 14, 677-678.	1.2	0

#	Article	IF	Citations
145	Conference Scene: A selected review of abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology. CNS Oncology, 2013, 2, 117-120.	3.0	0
146	Does early identification of low-grade glioma growth impact outcome?. Neuro-Oncology, 2014, 16, 1296-1296.	1.2	0
147	A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO). CNS Oncology, 2016, 5, 115-119.	3.0	0
148	Neuro-oncology: a selected review of ASCO 2016 abstracts. CNS Oncology, 2016, 5, 193-198.	3.0	0
149	Neuro-oncology overview. , 2016, , 557-558.		0
150	"You can observe a lot by just watching―(Yogi Berra). Neuro-Oncology, 2022, 24, 125-126.	1.2	0
151	Leptomeningeal metastasis., 2022,, 133-143.		0